

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Alarests - (Alarests -

APPLICATION NO.	FILING DATE	FIRST NAME:	~ VENIOR	ATTORNEY DOCKET NO	CONFIRMATION NO
09 768,080	01/23/2001	David A	. Estell	GC527C3	2502
5100 7:	590 09 27 2002				
GENENCOR INTERNATIONAL, INC.				EXAMINER	
925 PAGE MILL ROAD PALO ALTO, CA 94304			SAUNDERS, DAVID A		
				ART UNIT	PAPER NUMBER
				1644	4.
				DATE MAILED: 09 27 2002	10

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

768080 ESTELL et al

Examiner Group Art Unit

5AUNDERS 1644

—The MAILING DATE of this communication appears on the cover sheet beneath the correspondence address— Peri d for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, such period shall, by default, expire SIX (6) MONTHS from the mailing date of this communication . - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). **Status** Responsive to communication(s) filed on ____ ☐ This action is FINAL. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 1 1; 453 O.G. 213. 7-10, 14-27 _____is/are pending in the application. Claim(s) ___ is/are withdrawn from consideration. Of the above claim(s)_ is/are allowed. Claim(s)_ _____ is/are rejected. Claim(s) ____is/are objected to. Claim(s) _____ are subject to restriction or election requirement. **Application Papers** See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. The proposed drawing correction, filed on _______ is approved disapproved. ____ is/are objected to by the Examiner. The drawing(s) filed on____ The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner. Pri rity under 35 U.S.C. § 119 (a)-(d) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 11 9(a)-(d). All Some* None of the CERTIFIED copies of the priority documents have been received. received in Application No. (Series Code/Serial Number)_ received in this national stage application from the International Bureau (PCT Rule 1 7.2(a)). *Certified copies not received: Attachm nt(s) Information Disclosure Statement(s), PTO-1449, Paper No(s). Interview Summary, PTO-413 Notice of Informal Patent Application, PTO-152 Notice of Reference(s) Cited, PTO-892 Notice of Draftsperson's Patent Drawing Review, PTO-948 Other___

Office Action Summary

U. S. Patent and Trademark Office PTO-326 (Rev. 9-97)

Part of Paper No. ___/

Application/Control Number: 09/768,080

Art Unit: 1644

Restriction to one of the following inventions is required under 35 U.S.C. 121:

Claims 7-10 and 14-15, drawn to altered polypeptides that produce a different immunogenic response that is a lowered immunogenic response, classified in class 435, subclass 183+ and class 530, subclass 350+.

Claims 7-8 and 14-15, drawn to altered drawn to altered polypeptides that produce a different immunogenic response that is an increased immunogenic response, classified in class 435, subclass 183+ and class 530, subclass 350+.

III. Claims 16-27, drawn to methods of testing for allergenicity using transgenic mice, classified in class 435, subclass 7.4+ and class 800, subclass 3.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the allergenicity of a polypeptide can be evaluated by other methods – e.g. by the in vitro proliferation of T-cells in response to the polypeptide.

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different effects – i.e. producing lowered vs. increased immunogenic responses. The motivation to alter polypeptides to produce lowered responses (e.g. lowered allergenic or

1 Color of the col

Application/Control Number: 09/768,080

Art Unit: 1644

autoimmune responses) would be different from the motivation to alter polypeptides to produce increased responses (e.g. vaccinations).

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject mater, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David A Saunders, PhD whose telephone number is 703-308-3976. The examiner can normally be reached on Mon.-Thu., 8:00 am-5:30 pm and on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 703-308-3973. The fax phone numbers for the responses to restrictions is 703-305-3704. <u>Use attached form.</u>

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

DAVID SAUNDERS
PRIMARY EXAMINER
ART UNIT 182



RESTRICTION ELECTION FACSIMILE TRANSMISSION

COMMENTS:	
PLEASE NOTE:	THIS FACSIMILE NUMBER IS TO BE USED ONLY FOR RESPONSES TO RESTRICTIONS.
FAX/TELECOPIER	NUMBER: (703) 305-3704
SERIAL NUMBER:	
ART UNIT:	
TO EXAMINER:	·
	• **
PHONE NUMBER:	_
PAGES, INCLUDIN	NG COVERSHEET:
FIRM:	
FROM/ATTORNEY	7 :

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 1096 OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR, PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.